Prednisone

• A Phase 3 Study of Brepocitinib in Adults with Active, Non-Infectious, Non-Anterior Uveitis (CLARITY) Ended
  2024-515089-15-00 Phase III 9 countries Priovant Therapeutics Inc.
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru… Ended
  2022-502168-19-00 Phase II 4 countries Incyte Corp.
• Study to treat adult patients with Very High-Risk T-cell Acute Lymphoblastic Leukemia (ALL) with Daratumumab in addition to the National ALL… Ended
  2024-511627-34-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Study to Assess the Efficacy and Safety of Golcadomide and Rituximab in Participants with Newly Diagnosed Advanced Stage Follicular Lympho… Ended
  2024-511304-16-00 Phase II 5 countries Celgene Corp.
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High-… Ended
  2023-510178-15-00 Phase III 17 countries Celgene Corp.
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i… Ended
  2023-506906-38-00 Phase III 17 countries AbbVie Deutschland GmbH & Co. KG
• A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended
  2023-503452-27-00 Phase III 7 countries Novartis Pharma AG
• A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patie… Ended
  2022-501493-19-00 Phase III 3 countries Curium Pet France
• Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer (PETRANHA) Ended
  2023-508536-64-00 Phase I/II 1 country AstraZeneca AB
• Single-cell deep phenotyping of B lymphocytes to personalize immunotherapy in patients with Myasthenia Gravis: clinical trial to evaluate th… Ended
  2024-518939-12-00 Phase III 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• A Randomized Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults … Ended
  2023-503640-14-00 Phase III 17 countries Amgen Inc.
• VERLEN - Phase II, Open-Label Study evaluating efficacy of Lenalidomide and Tafasitamab combination associated to Rituximab in frontline Dif… Ended
  2023-507286-25-00 Phase II 2 countries LYSARC
• Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with high tumor burden Follicular Lymph… Ended
  2024-511636-27-00 Phase III 1 country Fondazione Italiana Linfomi Ets
• An International, Randomized, Double-Blind, Phase III Study of Fuzuloparib Combined with Abiraterone Acetate and Prednisone (AA-P) versus Pl… Ended
  2023-509396-16-00 Phase III 6 countries Jiangsu Hengrui Pharmaceuticals Co. Ltd.
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• AIEOP-BFM 2017 POLAND - Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia - A randomized phas… Ended
  2024-517253-27-00 Phase III 1 country Medical University Of Silesia Katowice Poland
• The aim of the study is to evaluate the efficacy of Ponatinib, either alone or in combination with chemotherapy, in inducing remission in pa… Ended
  2024-516868-28-00 Phase II 1 country Fondazione Gimema Franco Mandelli Onlus
• A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended
  2023-509358-72-00 Phase III 9 countries Acerta Pharma B.V.
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-506365-64-00 Phase III 13 countries Janssen - Cilag International
• Study of Cabozantinib in Combination With Atezolizumab compared to Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castratio… Ended
  2024-516481-11-00 Phase III 9 countries Exelixis Inc.
• POLAR BEAR Ended
  2022-502887-19-00 Phase III 6 countries Region Skane
• Investigation of Radium-223 dichloride (Xofigo), a treatment that gives off radiation that helps kill cancer cells, compared to a treatment … Ended
  2023-505830-89-00 Phase IV 10 countries Bayer AG; Bayer Consumer Care AG
• MEthotrexate versus TOcilizumab for treatment of GIant cell Arteritis: a multicenter, randomized, controlled trial Ended
  2024-512269-14-00 Phase III 1 country Centre Hospitalier Universitaire De Dijon
• Efficacy and Safety of Benralizumab in EGPA compared to mepolizumab. Ended
  2023-510248-19-00 Phase III 4 countries AstraZeneca AB

Showing 73–96 of 126 trials